Michael König

Mr. Michael KÖNIG is Adviser for Platform Regulation and the Digital Markets Act in the European Commission’s Directorate-General for Communications Networks, Content and Technology (DG CNECT). He was front line negotiator for the Digital Markets Act and will oversee its implementation in DG CNECT.

Before taking up his position in DG CNECT, Mr König was several years Deputy Head of Unit in the European Commission’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (GROW) in the unit responsible for Online services. He was primarily responsible for B2B relations regarding online platforms and negotiated the Regulation on fairness in platform-to-business relations (P2B Regulation).

Mr König joined the European Commission in 2001 in the Directorate-General for Competition. His assignments included a position as advisor to Directorate-General’s top management and a secondment to the OECD, before he joined the Internal Market Directorate-General in 2008. There he held positions in various policy areas including intellectual property, financial services and public procurement.

Before joining the Commission, Mr. König worked for several years in the German Competition Authority and an international law firm.

Mr. König graduated in Law and Economics, and holds a PhD degree in Competition Law.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More